All Stories

  1. Evidence-Based Medicine versus Personalized Medicine when attempting to block complement in IgA nephropathy
  2. Recognition and blocking of SARS-CoV-2 variants by Mannose-Binding Lectin
  3. The long Pentraxin PTX3 serves as an early predictive biomarker of co-infections in COVID-19
  4. The long Pentraxin PTX3 serves as an early predictive biomarker of co-infections in COVID-19
  5. 29 Humoral innate immunity and acute phase proteins in COVID-19
  6. 169 Involvement of PTX3 and MBL in the clearance of SARS-CoV-2 infected lung airway epithelial cells
  7. 115 The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2
  8. Reply to: Hultström et al., Genetic determinants of mannose-binding lectin activity predispose to thromboembolic complications in critical COVID-19. Mannose-binding lectin genetics in COVID-19
  9. Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules
  10. Where Are We with RPE Replacement Therapy? A Translational Review from the Ophthalmologist Perspective
  11. The Long Pentraxin PTX3 as a New Biomarker and Pharmacological Target in Age-Related Macular Degeneration and Diabetic Retinopathy
  12. Differential expression and regulation of MS4A family members in myeloid cells in physiological and pathological conditions
  13. Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules
  14. The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell–mediated resistance to metastasis
  15. TNF-Stimulated Gene-6 Is a Key Regulator in Switching Stemness and Biological Properties of Mesenchymal Stem Cells
  16. The Long Pentraxin PTX3 as a Link Between Innate Immunity, Tissue Remodeling, and Cancer
  17. Interaction of C1q With Pentraxin 3 and IgM Revisited: Mutational Studies With Recombinant C1q Variants
  18. An antipsychotic drug exerts anti-prion effects by altering the localization of the cellular prion protein
  19. Humanin Specifically Interacts with Amyloid-β Oligomers and Counteracts Their in vivo Toxicity
  20. Fingolimod Limits Acute Aβ Neurotoxicity and Promotes Synaptic Versus Extrasynaptic NMDA Receptor Functionality in Hippocampal Neurons
  21. An antibody specific for prion protein detects toxic amyloid-beta oligomers
  22. A relevant pharmacological target in TBI
  23. A New Surface Plasmon Resonance Assay for In Vitro Screening of Mannose-Binding Lectin Inhibitors
  24. The new β amyloid-derived peptide Aβ1–6A2V-TAT(D) prevents Aβ oligomer formation and protects transgenic C. elegans from Aβ toxicity
  25. A cationic tetrapyrrole inhibits toxic activities of the cellular prion protein
  26. Clusterin Binds to Aβ1–42Oligomers with High Affinity and Interferes with Peptide Aggregation by Inhibiting Primary and Secondary Nucleation
  27. Scaffold Optimisation of Tetravalent Antagonists of the Mannose Binding Lectin
  28. Exploring the role of MKK7 in excitotoxicity and cerebral ischemia: a novel pharmacological strategy against brain injury
  29. An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode
  30. CLUSTERIN REDUCES THE FORMATION OF BIOLOGICAL RELEVANT TOXIC SOLUBLE ABETA1-42 OLIGOMERS
  31. A New Surface Plasmon Resonance-Based Immunoassay for Rapid, Reproducible and Sensitive Quantification of Pentraxin-3 in Human Plasma
  32. Expression of A2V-mutated Aβ in Caenorhabditis elegans results in oligomer formation and toxicity
  33. Novel approaches for studying amyloidogenic peptides/proteins
  34. Epitope scanning indicates structural differences in brain-derived monomeric and aggregated mutant prion proteins related to genetic prion diseases
  35. New insights into the molecular mechanisms underlying sensitivity/resistance to the atypical retinoid ST1926 in acute myeloid leukaemia cells: The role of histone H2A.Z, cAMP-dependent protein kinase A and the proteasome
  36. An N-terminal Fragment of the Prion Protein Binds to Amyloid-β Oligomers and Inhibits Their Neurotoxicityin Vivo
  37. Good gene, bad gene: New APP variant may be both
  38. Applications of Surface Plasmon Resonance (SPR) for the Characterization of Nanoparticles Developed for Biomedical Purposes
  39. Targeting Mannose-Binding Lectin Confers Long-Lasting Protection With a Surprisingly Wide Therapeutic Window in Cerebral Ischemia
  40. Detection of toxic amyloid beta oligomers by a novel Surface Plasmon Resonance-based immunoassay
  41. Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis
  42. A modified protocol to prepare seed-free starting solutions of amyloid-β (Aβ)1–40 and Aβ1–42 from the corresponding depsipeptides
  43. Use of surface plasmon resonance to study the elongation kinetics and the binding properties of the highly amyloidogenic Aβ1–42 peptide, synthesized by depsi-peptide technique
  44. Functional analysis of a murine monoclonal antibody against the repetitive region of the fibronectin‐binding adhesins fibronectin‐binding protein A and fibronectin‐binding protein B from Staphylococcus aureus
  45. Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein
  46. Non-peptidic Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors
  47. Immunopurification of Pathological Prion Protein Aggregates
  48. Recombinant C1 inhibitor in brain ischemic injury